The research team has already found that preserving lymph nodes during treatment initiation helps the body's immune system ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...

Head and neck cancers remain one of the most significant global health challenges. According to the latest data, in 2023 ...

CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 ...

treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune ...

NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines ...

Since immunotherapy has been approved by the Food and Drug Administration to treat advanced head and neck cancer (HNC), it has offered patients new ...

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).

Jonathan Riess, MD, MS, director of thoracic medicine at UC Davis Health, gave insight into the rationale and efficacy data for combining cancer vaccine IO102-IO103 with pembrolizumab in advanced ...

RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both ...